Health Industry

"Health Industry" Main

Latest Morning Briefing Stories

California Offers Lifeline to 17 Hospitals, Including up to $52 Million for Madera

California’s new lending program for distressed hospitals will provide Madera Community Hospital with interest-free loans of up to $52 million if it can agree on a viable reopening plan with Adventist Health. The state will offer an additional $240.5 million in interest-free loans to 16 other troubled hospitals.

The Painful Pandemic Lessons Mandy Cohen Carries to the CDC

Mandy Cohen, the new director of the Centers for Disease Control and Prevention, earned praise for her leadership and communication as the face of North Carolina’s response to covid-19. People in the state’s most vulnerable communities tell a more complicated story.

Doctors and Patients Try to Shame Insurers Online to Reverse Prior Authorization Denials

Prior authorization is a common tool used by health insurers for many tests, procedures, and prescriptions. Frustrated by the process, patients and doctors have turned to social media to publicly shame insurance companies and elevate their denials for further review.

The CDC Works to Overhaul Lab Operations After Covid Test Flop

In early 2020, U.S. public health labs received covid-19 tests from the Centers for Disease Control and Prevention that were flawed, as a result of poor design and contamination. Now the CDC is overhauling its lab operations, but efforts to be better prepared for future threats won’t be easy, observers say.

Tribal Health Workers Aren’t Paid Like Their Peers. See Why Nevada Changed That.

Community health workers, who often help patients get to their appointments and pick up prescriptions for them, have increasingly been recognized as an integral part of treating chronic illnesses. But state-run Medicaid programs don’t always reimburse them equally, usually excluding those who work on tribal lands.

A Peek at Big Pharma’s Playbook That Leaves Many Americans Unable to Afford Their Drugs

Brand-name drug prices in the U.S. — more than three times the price in other developed countries — are related neither to the amount of research and development required to bring them to market nor their therapeutic value, recent research shows. Have drugmakers overplayed their hand?